Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is available in oral (delayed-release tablets, suspension) and intravenous formulations.
## Primary Indications
* Treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-related mucosal injury (IV, off-label).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg/day have been utilized; clinical response dictates frequency and titration.
* **Stress Ulcer Prophylaxis (Off-label):** 40 mg IV once daily or every 12 hours based on institutional protocol.
## Pediatric Dosing
* **GERD (Erosive Esophagitis) ≥ 5 years:**
* 15 kg to < 40 kg: 20 mg once daily.
* ≥ 40 kg: 40 mg once daily.
* **Note:** Efficacy and safety for pediatric patients < 5 years are not established for the delayed-release formulation.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Mild to moderate impairment usually requires no adjustment; severe impairment may warrant reduced dosing frequency (e.g., every other day), though specific thresholds vary by clinical judgment.
* **Geriatric:** No adjustment needed.
## Contraindications
* Hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., other PPIs).
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and increased fracture risk.
## Key Drug Interactions
* **pH-dependent drugs:** May decrease absorption of drugs such as atazanavir, nelfinavir, iron salts, and certain azole antifungals (ketoconazole, itraconazole).
* **Methotrexate:** Potential for increased serum levels and toxicity, particularly in high-dose therapy.
* **Cyp450:** Generally has a lower potential for drug-drug interactions compared to omeprazole, though clinical monitoring is still advised with narrow therapeutic index medications.
## Monitoring
* **Magnesium:** Check baseline and monitor periodically during long-term therapy (> 1 year) or if used concurrently with diuretics or digoxin.
* **B12:** Monitor if on long-term therapy.
* **Renal function:** Monitor for symptoms of interstitial nephritis (rare).
* **Clinical response:** Assess for symptom resolution to prevent unnecessary long-term PPI use.
## Clinical Pearls
* **Administration:** Oral delayed-release tablets should be swallowed whole; do not crush or chew. May be administered without regard to food.
* **IV Administration:** IV dose is typically administered as a 15-minute infusion or a 2-minute bolus (depending on institutional policy).
* **De-prescribing:** Always prioritize the "lowest effective dose for the shortest duration." PPIs are frequently over-prescribed for patients without a clear gastrointestinal indication.
* **Rebound:** Patients may experience rebound hypersecretion upon discontinuation; consider tapering for long-term users.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and institutional protocols vary. Always verify specific dosing, safety, and contraindications against the latest manufacturer prescribing information or clinical decision support tools before initiating therapy.
